Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.

By WebmasterNovember 9, 2023November 1st, 2024No Comments

Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.

Previous PostONCO, Inc. Announces Strategic Partnership with Oncora Medical to Launch Data-Driven Software Automation to Enhance Patient Care and Oncology Data Management.
Next PostImmunome Reports Third Quarter 2023 Financial Results